Patent term extension Archives - Page 2 of 2 - World School of Life Sciences IP

Novo Nordisk’s Rivfloza™ gets the U.S. FDA approval for treatment of primary hyperoxaluria type 1 (PH1)

Tanu Goyal October 2, 2023

Novo Nordisk’s RivflozaTM gets the U.S. FDA approval for treatment of primary hyperoxaluria type 1 (PH1) On 29th September, Novo Nordisk obtained approval from the U.S.

Generics for Otezla® to be out in the United States in February 2028

Tanu Goyal September 14, 2023

Generics for Otezla® to be out in the United States in February 2028 Amgen’s oral phosphodiesterase-4 (PDE-4) inhibitor – Otezla® (Apremilast) is approved in the

Patent Term Extensions – A Lifeline to the Pharmaceutical Innovation

Tanu Goyal August 17, 2023

Patent Term Extensions – A Lifeline to the Pharmaceutical Innovation 1. What are Patent Term Extensions? How do they differ from Supplementary Protection Certificates?

WSLI

Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.